Pfizer and Strides Arcolab to Collaborate on Generic Products
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Pfizer and Strides Arcolab have announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit.
These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest. The financial terms of the supply agreement were not disclosed.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship.”
The companies believe this is a highly complementary collaboration, which is expected to deliver 40 off-patent products, many of which are oncology therapeutics, to healthcare providers and patients in the U.S., by joining Pfizer’s solid commercial infrastructure with Strides’s high-quality manufacturing capabilities. The first of the products commercialized under this collaboration is expected to be launched in 2010.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship," said David Simmons, president and general manager of Pfizer’s Established Products Business Unit. “In addition, this agreement brings the total number of products in-licensed by our Established Products Business Unit to more than 200 -- resulting in a total business unit portfolio of approximately 600 high-quality, reliable, and cost effective products for patients.”
“Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options,” said Arun Kumar, Strides Founder and Managing Director. “We have established a reputation for efficient formulation development and technologies, manufacturing, and operational flexibility and are looking forward to bringing these strengths to bear in our collaboration with Pfizer.”
These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest. The financial terms of the supply agreement were not disclosed.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship.”
The companies believe this is a highly complementary collaboration, which is expected to deliver 40 off-patent products, many of which are oncology therapeutics, to healthcare providers and patients in the U.S., by joining Pfizer’s solid commercial infrastructure with Strides’s high-quality manufacturing capabilities. The first of the products commercialized under this collaboration is expected to be launched in 2010.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship," said David Simmons, president and general manager of Pfizer’s Established Products Business Unit. “In addition, this agreement brings the total number of products in-licensed by our Established Products Business Unit to more than 200 -- resulting in a total business unit portfolio of approximately 600 high-quality, reliable, and cost effective products for patients.”
“Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options,” said Arun Kumar, Strides Founder and Managing Director. “We have established a reputation for efficient formulation development and technologies, manufacturing, and operational flexibility and are looking forward to bringing these strengths to bear in our collaboration with Pfizer.”
